• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可溶性 TWEAK 血浆水平可预测人类腹主动脉瘤的扩张。

Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms.

机构信息

Vascular Research Lab, IIS-Fundación Jiménez Díaz, Autónoma University, Av Reyes Católicos 2, 28040 Madrid, Spain.

出版信息

Atherosclerosis. 2011 Feb;214(2):486-9. doi: 10.1016/j.atherosclerosis.2010.11.009. Epub 2010 Nov 12.

DOI:10.1016/j.atherosclerosis.2010.11.009
PMID:21130992
Abstract

OBJECTIVES

Diminished soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) concentrations are associated with cardiovascular diseases. We have analyzed sTWEAK levels and its relation with expansion rate in subjects with abdominal aortic aneurysm (AAA).

METHODS

sTWEAK levels were measured by ELISA.

RESULTS

sTWEAK concentrations were diminished in small AAA (≤ 5 cm; 353 ± 12 pg/mL; n = 25, p = 0.03) and large AAA (>5 cm; 315 ± 21 pg/mL; n = 18, p = 0.004) compared with healthy subjects (411 ± 22 pg/mL; n=27). Moreover, sTWEAK concentrations were negatively associated with AAA size (r = -0.4; p = 0.008). sTWEAK was also negatively associated with AAA expansion rate with 5 years of follow-up (n = 79, r = -0.263; p = 0.031). Multivariate regression analysis revealed that sTWEAK levels were independently associated with AAA growth rate (β = -0.208; p = 0.046).

CONCLUSIONS

sTWEAK plasma levels were decreased in subjects with AAA and were independently related with AAA expansion rate indicating that this protein could be a novel diagnostic and prognostic biomarker of AAA.

摘要

目的

可溶性肿瘤坏死因子样弱凋亡诱导剂(sTWEAK)浓度降低与心血管疾病有关。我们分析了腹主动脉瘤(AAA)患者的 sTWEAK 水平及其与扩张率的关系。

方法

通过 ELISA 测定 sTWEAK 水平。

结果

与健康受试者(n=27,411±22pg/ml)相比,小 AAA(≤5cm;n=25,353±12pg/ml,p=0.03)和大 AAA(>5cm;n=18,315±21pg/ml,p=0.004)的 sTWEAK 浓度降低。此外,sTWEAK 浓度与 AAA 大小呈负相关(r=-0.4;p=0.008)。sTWEAK 与 5 年随访期间的 AAA 扩张率也呈负相关(n=79,r=-0.263;p=0.031)。多变量回归分析显示,sTWEAK 水平与 AAA 生长率独立相关(β=-0.208;p=0.046)。

结论

AAA 患者的 sTWEAK 血浆水平降低,与 AAA 扩张率独立相关,表明该蛋白可能是 AAA 的一种新的诊断和预后生物标志物。

相似文献

1
Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms.可溶性 TWEAK 血浆水平可预测人类腹主动脉瘤的扩张。
Atherosclerosis. 2011 Feb;214(2):486-9. doi: 10.1016/j.atherosclerosis.2010.11.009. Epub 2010 Nov 12.
2
Plasma profiling by a protein array approach identifies IGFBP-1 as a novel biomarker of abdominal aortic aneurysm.蛋白质芯片分析血浆蛋白谱发现 IGFBP-1 是腹主动脉瘤的一种新的生物标志物。
Atherosclerosis. 2012 Apr;221(2):544-50. doi: 10.1016/j.atherosclerosis.2012.01.009. Epub 2012 Jan 25.
3
Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases.可溶性肿瘤坏死因子样弱凋亡诱导因子(TWEAK)水平可预测无临床心血管疾病受试者中颈动脉粥样硬化斑块的存在。
Atherosclerosis. 2015 Apr;239(2):358-63. doi: 10.1016/j.atherosclerosis.2015.01.040. Epub 2015 Feb 7.
4
Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.慢性肾脏病患者中可溶性肿瘤坏死因子样弱凋亡诱导因子与主要不良心血管事件
Clin J Am Soc Nephrol. 2016 Mar 7;11(3):413-22. doi: 10.2215/CJN.07900715. Epub 2016 Jan 4.
5
ApoA-I/HDL-C levels are inversely associated with abdominal aortic aneurysm progression.载脂蛋白A-I/高密度脂蛋白胆固醇水平与腹主动脉瘤进展呈负相关。
Thromb Haemost. 2015 Jun;113(6):1335-46. doi: 10.1160/TH14-10-0874. Epub 2015 Mar 19.
6
Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.可溶性肿瘤坏死因子样弱凋亡诱导因子与慢性肾脏病患者的动脉粥样硬化负担相关。
J Nephrol. 2013 Nov-Dec;26(6):1105-13. doi: 10.5301/jn.5000245. Epub 2013 Jan 28.
7
Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.可溶性 TWEAK 和 CD163/TWEAK 比值对周围动脉疾病患者长期心血管死亡率的影响。
Atherosclerosis. 2011 Dec;219(2):892-9. doi: 10.1016/j.atherosclerosis.2011.09.016. Epub 2011 Sep 16.
8
Increased plasma levels of NGAL, a marker of neutrophil activation, in patients with abdominal aortic aneurysm.腹主动脉瘤患者血浆 NGAL 水平升高,NGAL 是中性粒细胞活化的标志物。
Atherosclerosis. 2012 Feb;220(2):552-6. doi: 10.1016/j.atherosclerosis.2011.11.023. Epub 2011 Nov 25.
9
Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.外周动脉疾病与高 CD163/TWEAK 血浆比值相关。
Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1253-62. doi: 10.1161/ATVBAHA.110.203364. Epub 2010 Mar 18.
10
Identification of peroxiredoxin-1 as a novel biomarker of abdominal aortic aneurysm.鉴定过氧化物酶 1 为腹主动脉瘤的新型生物标志物。
Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):935-43. doi: 10.1161/ATVBAHA.110.214429. Epub 2011 Jan 27.

引用本文的文献

1
Plasma complement component C2: a potential biomarker for predicting abdominal aortic aneurysm related complications.血浆补体成分 C2:预测腹主动脉瘤相关并发症的潜在生物标志物。
Sci Rep. 2022 Dec 8;12(1):21252. doi: 10.1038/s41598-022-24698-1.
2
Circulating Biomarkers for the Prediction of Abdominal Aortic Aneurysm Growth.用于预测腹主动脉瘤生长的循环生物标志物
J Clin Med. 2021 Apr 16;10(8):1718. doi: 10.3390/jcm10081718.
3
Challenges of applying circulating biomarkers for abdominal aortic aneurysm progression.应用循环生物标志物检测腹主动脉瘤进展的挑战。
Exp Biol Med (Maywood). 2021 May;246(9):1054-1059. doi: 10.1177/1535370221992530. Epub 2021 Feb 27.
4
The Diagnostic Value of sTWEAK in Acute Ischemic Stroke.sTWEAK 在急性缺血性脑卒中中的诊断价值。
Balkan Med J. 2020 Oct 23;37(6):336-340. doi: 10.4274/balkanmedj.galenos.2020.2020.2.45. Epub 2020 Aug 28.
5
Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges.肿瘤坏死因子样弱凋亡诱导因子(TWEAK)/成纤维细胞生长因子诱导 14 (Fn14)轴在心血管疾病中的作用:进展与挑战。
Cells. 2020 Feb 11;9(2):405. doi: 10.3390/cells9020405.
6
Systematic Review of Circulating, Biomechanical, and Genetic Markers for the Prediction of Abdominal Aortic Aneurysm Growth and Rupture.用于预测腹主动脉瘤生长和破裂的循环、生物力学和遗传标志物的系统评价。
J Am Heart Assoc. 2018 Jun 30;7(13):e007791. doi: 10.1161/JAHA.117.007791.
7
Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection.可溶性肿瘤坏死因子样弱凋亡诱导因子(TWEAK)可能预测接受治疗的HIV感染患者的颈动脉粥样硬化。
HIV Clin Trials. 2017 Jul;18(4):156-163. doi: 10.1080/15284336.2017.1366001. Epub 2017 Aug 22.
8
TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFκB.肿瘤坏死因子样弱凋亡诱导因子(TWEAK)通过经典和非经典激活核因子κB(NFκB)促进磷酸盐诱导的血管平滑肌细胞钙化。
Cell Death Dis. 2016 Jul 21;7(7):e2305. doi: 10.1038/cddis.2016.220.
9
Soluble TNF-Like Weak Inducer of Apoptosis as a New Marker in Preeclampsia: A Pilot Clinical Study.可溶性肿瘤坏死因子样凋亡弱诱导剂作为子痫前期的一种新标志物:一项初步临床研究
Dis Markers. 2016;2016:5930589. doi: 10.1155/2016/5930589. Epub 2016 Feb 17.
10
Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.慢性肾脏病患者中可溶性肿瘤坏死因子样弱凋亡诱导因子与主要不良心血管事件
Clin J Am Soc Nephrol. 2016 Mar 7;11(3):413-22. doi: 10.2215/CJN.07900715. Epub 2016 Jan 4.